Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Relapse has been reported after stopping nucleos(t)ide (NUC) therapy in the majority of chronic HBeAg negative hepatitis patients. However, the ideal treatment duration of HBeAg negative chronic hepatitis B (CHB)is not well known. We investigated the frequency of relapse in HBeAg negative CHB patients receiving NUC therapy. Methods: The NUC therapy was discontinued at least 3 times undetectable level of HBV DNA leave 6 months space in 45 patients. Clinical relapse was defined as HBV DNA >2,000 IU/mL and alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 times of upper limit of normal range. Virological relapse was defined as HBV DNA >2,000IU/mL. Results: Clinical relapse developed in 16 (35.6%) and 24 (53.3%) patients after stopping therapy at 6 months and 12months off therapy, respectively. Virological relapse developed 22 (48.9%) and 33 (73.3%) patients at 6 months and 12months off therapy. The factors such as age, gender, cirrhosis, baseline AST, ALT, HBV DNA levels, treatment duration,and consolidation duration were analyzed to investigate the predictive factors associated with 1 year sustained response. Of these factors, cirrhosis (86.1% in CHB, 22.2% in LC) was significantly associated with 1 year virological relapse rate. Baseline HBV DNA and total treatment duration tended to be associated with virological relapse. Conclusions: Virological relapse developed in the majority (73.3%) of HBeAg negative CHB patients and clinical relapse developed in the half (53.3%) of patients at 1 year off therapy. Cirrhosis may be associated with the low rate of virological relapse. (Clin Mol Hepatol 2013;19:300-307)
Abstract
Background/Aims: Relapse has been reported after stopping nucleos(t)ide (NUC) therapy in the majority of chronic HBeAg negative hepatitis patients. However, the ideal treatment duration of HBeAg negative chronic hepatitis B (CHB)is not well known. We investigated the frequency of relapse in HBeAg negative CHB patients receiving NUC therapy. Methods: The NUC therapy was discontinued at least 3 times undetectable level of HBV DNA leave 6 months space in 45 patients. Clinical relapse was defined as HBV DNA >2,000 IU/mL and alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 times of upper limit of normal range. Virological relapse was defined as HBV DNA >2,000IU/mL. Results: Clinical relapse developed in 16 (35.6%) and 24 (53.3%) patients after stopping therapy at 6 months and 12months off therapy, respectively. Virological relapse developed 22 (48.9%) and 33 (73.3%) patients at 6 months and 12months off therapy. The factors such as age, gender, cirrhosis, baseline AST, ALT, HBV DNA levels, treatment duration,and consolidation duration were analyzed to investigate the predictive factors associated with 1 year sustained response. Of these factors, cirrhosis (86.1% in CHB, 22.2% in LC) was significantly associated with 1 year virological relapse rate. Baseline HBV DNA and total treatment duration tended to be associated with virological relapse. Conclusions: Virological relapse developed in the majority (73.3%) of HBeAg negative CHB patients and clinical relapse developed in the half (53.3%) of patients at 1 year off therapy. Cirrhosis may be associated with the low rate of virological relapse. (Clin Mol Hepatol 2013;19:300-307)
참고문헌 (20)
- Lai CL, "Viral hepatitis B", Lancet, 362, pp.2089~2094 (2003)
- Lee WM, "Hepatitis B virus infection", N Engl J Med, 337, pp.1733~1745 (1997)
- Funk ML, "World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants", J Viral Hepat, 9, pp.52~61 (2002)
- Manesis EK, "HBeAg-negative chronic hepatitis B: from obscurity to prominence", J Hepatol, 45, pp.343~346 (2006)
- Papatheodoridis GV, "Diagnosis and management of pre-core mutant chronic hepatitis B", J Viral Hepat, 8, pp.311~321 (2001)
- Hadziyannis SJ, "Hepatitis B e antigen-negative chronic hepatitis B", Hepatology, 34, pp.617~624 (2001)
- Papatheodoridis GV, "Review article: current management of chronic hepatitis B", Aliment Pharmacol Ther, 19, pp.25~37 (2004)
- Yuen MF, "Treatment of chronic hepatitis B: Evolution over two decades", J Gastroenterol Hepatol, 26(Suppl 1), pp.138~143 (2011)
- Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update", Hepatol Int, 2, pp.263~283 (2008)
- Lee M, "Hepatitis B: modern end points of treatment and the specter of viral resistance", Gastroenterol Clin North Am, 40, pp.495~505 (2011)
- 이홍섭, "Prediction of compensated liver cirrhosis by ultrasonography and routine blood tests in patients with chronic viral hepatitis", Clinical and Molecular Hepatology, 16(4), pp.369~375 (2010), 대한간학회
- Soon Sun Kim, "Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B", Gut and Liver, 5(3), pp.278~287 (2011), 거트앤리버 발행위원회
- Santantonio T, "Long-term follow-up of patients with anti-HBe", HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine, 2000, pp.32, 300~306
- Shouval D, "Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy", J Hepatol, 50, pp.289~295 (2009)
- Fung SK, "Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigennegative chronic hepatitis B", J Viral Hepat, 11, pp.432~438 (2004)
- Liu F, "Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients", J Gastroenterol Hepatol, 26, pp.456~460 (2011)
- Hadziyannis S, "Outcome of HBeAg-negative chronic hepatitis B (CHB) 5years after discontinuation of long term adefovir dipivoxil (ADL) treatment", J Hepatol, 50(Suppl 1), pp.S9~S10 (2009)
- Jeng W, "Off therapy durability in chronic hepatitis B e antigen negative patients treated with entecavir", Hepatology, 54(Suppl 1), pp.1014A~ (2011)
- 백용한, "Clinical Efficacy of a 24-months Course of Lamivudine Therapy in Patients with HBeAg Negative Chronic Hepatitis B: A Longterm Prospective Study", Journal of Korean Medical Science, 25(6), pp.882~887 (2010), 대한의학회
- Ha M, "A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir", Arch Virol, 157, pp.285~290 (2012)